Meeting NewsVideo

VIDEO: Aerie to test Rho kinase inhibitor implant for glaucoma

SAN FRANCISCO — At the Glaucoma 360: New Horizons Forum, Casey C. Kopczynski, PhD, chief scientific officer and co-founder of Aerie Pharmaceuticals, explains the company’s plan to test its AR-13503 sustained-release Rho kinase inhibitor implant for the treatment of glaucoma.

SAN FRANCISCO — At the Glaucoma 360: New Horizons Forum, Casey C. Kopczynski, PhD, chief scientific officer and co-founder of Aerie Pharmaceuticals, explains the company’s plan to test its AR-13503 sustained-release Rho kinase inhibitor implant for the treatment of glaucoma.

    See more from Glaucoma 360